Efficacy of fleroxacin in experimental methicillin-resistant Staphylococcus aureus endocarditis

Antimicrob Agents Chemother. 1989 Apr;33(4):519-21. doi: 10.1128/AAC.33.4.519.

Abstract

The efficacy of fleroxacin versus that of vancomycin was assessed by using the rabbit model of methicillin-resistant Staphylococcus aureus endocarditis. Animals were treated with fleroxacin (30 mg/kg of body weight every 8 h) or vancomycin (17.5 mg/kg every 6 h) for 4 days. These antimicrobial agents were equally effective in clearing bacteremia, reducing bacterial counts in vegetations and tissues, and curing endocarditis. However, resistance to fleroxacin at fivefold the MIC arose in the test strain of S. aureus in 8% of animals that received the drug. We conclude that fleroxacin is as efficacious as vancomycin in this model of a serious systemic S. aureus infection, but modest resistance to fleroxacin may develop during therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Ciprofloxacin / analogs & derivatives*
  • Ciprofloxacin / pharmacokinetics
  • Ciprofloxacin / pharmacology
  • Ciprofloxacin / therapeutic use
  • Drug Resistance, Microbial
  • Endocarditis, Bacterial / drug therapy*
  • Endocarditis, Bacterial / microbiology
  • Fleroxacin
  • Male
  • Methicillin / pharmacology
  • Microbial Sensitivity Tests
  • Penicillin Resistance
  • Rabbits
  • Staphylococcal Infections / drug therapy*
  • Staphylococcal Infections / microbiology
  • Staphylococcus aureus / drug effects

Substances

  • Ciprofloxacin
  • Fleroxacin
  • Methicillin